30 closest matches · ranked by relevance
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo — 45; 32…
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases
Influenza
Primary: Occurrences of Culture- or Polymerase Chain Reaction (PCR)-Confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Protocol-defined…
Influenza
Primary: Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains — 7; 9; 44; 2 Subjects — p=<0.001
Infections, Rotavirus
Primary: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain — 30; 26; 56; 70 subjects
Rotavirus Infections
Primary: Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose. — 15; 54…
Hepatitis
Primary: Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period — 0.0; 6.9; 0.3; 0.1 Percent of Participants
18-42 Year Old Healthy Vaccinia-naïve Subjects
Primary: Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at the Peak Visits — 153.5; 79.3 Titer
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Influenza
Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match) — 17.9; 18.0 percentage of participants — p=0.996
Respiratory Syncytial Virus Infections
Primary: Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single…
SARS-CoV-2 Infection · HIV Infections · COVID-19
Primary: Part A: Number of Participants With a First Occurrence of CDC-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group…
Immunization Against COVID-19
Primary: The Number of Laboratory-confirmed SARS-CoV-2 Infections. — 7; 22 Participants — p=0.0046
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Eastern Equine Encephalitis
Primary: Subject Response Rates for PRNT80 Titers — 39; 28; 48; 79 Participants
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
SARS-CoV-2
Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Meningococcal Disease
Primary: Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the…
Malaria · Malaria,Falciparum
Primary: Number of Serious Adverse Events and Grade 3 Adverse Events — 0; 0; 0; 0 adverse events
Rotavirus Infections
Primary: Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo — 6; 5 Participants — p=0.006
Healthy Volunteers
Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Hepatitis B
Primary: Seroconversion Rate — 47; 46 Participants — p=1
COVID-19
Primary: Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29 — 2340.9; 1753.8 AU/mL
Influenza
Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). — 6.7; 15.8 percentage of participants — p=<0.0001
Herpes Simplex Type 2
Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change
HPV 16 Infection
Primary: Incidence of Persistent HPV 16 Infection — 0.3; 4.9 Incidence per 100 person-years